Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AEON

AEON Biopharma Inc.

Last Close
May 02 • 11:45AM ET
3.43
Dollar change
-0.14
Percentage change
-3.92 		%
Scroll to Statements
Index- P/E- EPS (ttm)-1.00 Insider Own70.48% Shs Outstand37.16M Perf Week-19.29%
Market Cap129.62M Forward P/E- EPS next Y-1.16 Insider Trans0.00% Shs Float11.16M Perf Month-57.60%
Income-24.19M PEG- EPS next Q-0.31 Inst Own13.65% Short Float3.88% Perf Quarter-51.96%
Sales0.00M P/S- EPS this Y-661.90% Inst Trans4.48% Short Ratio6.26 Perf Half Y-35.04%
Book/sh-2.48 P/B- EPS next Y1.69% ROA-13.94% Short Interest0.43M Perf Year-66.34%
Cash/sh0.14 P/C25.12 EPS next 5Y- ROE-27.38% 52W Range3.37 - 17.17 Perf YTD-52.36%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-80.02% Beta0.77
Dividend TTM- Quick Ratio0.48 Sales past 5Y0.00% Gross Margin- 52W Low1.78% ATR (14)0.96
Dividend Ex-Date- Current Ratio0.48 EPS Y/Y TTM-639.39% Oper. Margin0.00% RSI (14)28.44 Volatility23.31% 14.75%
Employees10 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price18.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-42448.15% Payout- Rel Volume1.06 Prev Close3.57
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 29 AMC Avg Volume69.14K Price3.43
SMA20-44.43% SMA50-64.46% SMA200-52.28% Trades Volume27,736 Change-3.92%
Date Action Analyst Rating Change Price Target Change
Aug-18-23Initiated H.C. Wainwright Buy $18
Mar-30-24 10:53PM
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
(GlobeNewswire)
Mar-29-24 04:15PM
AEON Biopharma Announces Redemption of Public Warrants
(GlobeNewswire)
03:45PM
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Mar-19-24 04:30PM
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
(GlobeNewswire) -11.60%
04:29PM
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
(GlobeNewswire)
04:05PM Loading…
Jan-18-24 04:05PM
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
(GlobeNewswire)
Dec-12-23 08:00AM
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
(GlobeNewswire)
Nov-15-23 04:49AM
AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements
(GuruFocus.com) +7.61%
Nov-13-23 08:15AM
AEON Biopharma Reports Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-19-23 04:05PM
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
(GlobeNewswire)
Aug-29-23 08:00AM
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
(GlobeNewswire)
Aug-24-23 08:00AM
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
(GlobeNewswire) +14.91%
Aug-16-23 07:00AM
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
(GlobeNewswire) +7.06%
Jul-24-23 07:00AM
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
(GlobeNewswire) -15.13%
AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Strathspey Crown Holdings Grou10% OwnerAug 11 '23Sale10.007,380,39473,803,9402,031,773Aug 14 04:10 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.